ABC | Volume 114, Nº5, Maio 2020

Posicionamento Posicionamento da Sociedade Brasileira de Cardiologia para Gravidez e Planejamento Familiar na Mulher Portadora de Cardiopatia – 2020 Arq Bras Cardiol. 2020; 114(5):849-942 386. Sims DB, Vink J, Uriel N, Cleary KL, Smiley RM, JordeUP, et al. A successful pregnancy during mechanical circulatory device support. J Heart Lung Transplant. 2011;30(9):1065-7. 387. Enriquez AD, Economy KE, Tedrow UB. Contemporary management of arrhythmias during pregnancy. Circ Arrhythm Electrophysiol. 2014;7(5):961-7. 388. Silversides CK, Harris L, Haberer K, Sermer M, Colman JM, Siu SC. Recurrencerates ofarrhythmiasduringpregnancy inwomenwithprevious tachyarrhythmiaand impacton fetalandneonataloutcomes.Am JCardiol. 2006;97(8):1206-12. 389. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893-962. 390. Kockova R, Kocka V, Kiernan T, Fahy GJ. Ibutilide-induced cardioversion of atrial fibrillation during pregnancy. J Cardiovasc Electrophysiol. 2007;18(5):545-7. 391. Wang YC, Chen CH, SuHY, YuMH. The impact of maternal cardioversion on fetal haemodynamics. Eur J Obstet Gynecol Reprod Biol. 2006;126(2):268-9. 392. Natale A, Davidson T, Geiger MJ, Newby K. Implantable cardioverterdefibrillators and pregnancy: a safe combination? Circulation. 1997;96(9):2808-12. 393. Tripathi B, Kumar V, Pitiliya A, Arora S, Sharma P, Shah M, et al. Trends in Incidence and Outcomes of Pregnancy-Related Acute Myocardial Infarction (Froma Nationwide Inpatient Sample Database). Am J Cardiol. 2019;123(8):1220-7. 394. Mehta LS, Beckie TM, DeVon HA, Grines CL, Krumholz HM, Johnson MN, et al. Acute Myocardial Infarction in Women A Scientific Statement From the American Heart Association. Circulation. 2016;133(9):916-47. 395. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presentingwith ST-segment elevation: The Task Force for themanagement of acutemyocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119-77. 396. SousaGomesM,GuimarãesM,MontenegroN.Thrombolysisinpregnancy: a literature review. Matern Fetal Neonatal Med. 2019;32(14):2418-28. 397. Hayes SN, KimESH, Saw J, AdlamD, Arslanian-EngorenC, Economy KE, et al. Spontaneous Coronary Artery Dissection: Current State of the Science A Scientific Statement From the AmericanHeart Association. Circulation. 2018;137(19):e523-e557. 398. Thalmann M, Sodeck GH, Domanovits H, Grassberger M, Loewe C, Grimm M, et al. Acute type a aortic dissection and pregnancy: A population-based study. Eur J Cardiothorac Surg. 2011;39(6):e159-63. 399. Yates MT, Soppa G, Smelt J, Fletcher N, van Besouw JP, Thilaganathan B, et al. Perioperative management and outcomes of aortic surgery during pregnancy. J Thorac Cardiovasc Surg. 2015;149(2):607-10. 400. Brener MI, Keramati AR. Type B dissection in a pregnant womanmanaged with peripartum thoracic endovascular aortic repair. Circulation. 2016;133(5):e369-73. 401. SillesenM, Hjortdal V, VejlstrupN, Sørensen K. Pregnancy with prosthetic heart valves – 30 years’ nationwide experience in Denmark. Eur J Cardiothorac Surg. 2011;40(2):448-54. 402. Baumgartner H, Falk V, Bax JJ, De Bonis M, HammC, HolmPJ, et al. 2017 ESC/ EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2017;38(36):2739-91. 403. M Özkan, Çakal B, Karakoyun S, Gürsoy OM, Çevik C, Kalçık M, et al. Thrombolytic therapy for the treatment of prosthetic heart valve thrombosis in pregnancy with low-dose, slow infusion of tissue type plasminogen activator. Circulation. 2013;128(5):532-40. 404. Olasveengen TM, de Caen AR, Mancini ME, Maconochie IK, Aickin R, Atkins DL, et al. On behalf of the ILCORCollaborators. 2017 International Consensus on Cardiopulmonary Resuscitation and Emergency CardiovascularCareScienceWithTreatmentRecommendationssummary. Circulation. 2017;136(23):e424-40. 405. LinkMS, Berkow LC, Kudenchuk PJ, Halperin HR, Hess EP, Moitra VK, et al. Part 7: Adult Advanced Cardiovascular Life Support 2015 American Heart Association Guidelines Update for Cardiopulmonary resuscitation and EmergencyCardiovascularCare.Circulation.2015;132(18Suppl2):S444-64. 406. Kundra P, Khanna S, Habeebullah S, RavishankarM. Manual displacement of the uterus during caesarean section. Anaesthesia. 2007;62(5):460-5. 407. Nanson J, Elcock D, Williams M, Deakin CD. Do physiological changes in pregnancy change defibrillation energy requirements? Br J Anaesth. 2001;87(2):237-9. 408. Dorian P, Cass D, Schwartz B, Cooper R, Gelaznikas R, Barr A. Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation. N Engl J Med. 2002;346(12):884-90. 409. Jeejeebhoy F, Zelop CM, Lipman S, Carvalho B, Joglar J, Mhyre JM, et al. Cardiac Arrest in Pregnancy A Scientific Statement From the American Heart Association. Circulation. 2015;132(18):1747-73. 410. Einav S, Kaufman N, Sela HY. Maternal cardiac arrest and perimortem caesarean delivery: evidence or expert-based? Resuscitation. 2012;83(10):1191-200. 411. Lipman S, Cohen S, Einav S, Jeejeebhoy F, Mhyre JM, Morrison LJ, et al. The Society for Obstetric Anesthesia and Perinatology consensus statement on the management of cardiac arrest in pregnancy. Anesth Analg. 2014;118(5):1003-16. 412. Katz V, Balderston K, DeFreest M. Perimortem cesarean delivery: were our assumptions correct? Am J Obstet Gynecol. 2005;192(6):1916-20; discussion 1920-1. 413. DrenthenW, Boersma E, Balci A, Moons P, Roos-Hesselink JW, Mulder BJ, et al. Predictors of pregnancy complications in women with congenital heart disease. Eur Heart J. 2010;31(17):2124-32. 414. Balci A, Sollie-Szarynska KM, van der Bijl AG, Ruys TP, Mulder BJ, Roos-Hesselink JW, et al. Prospective validation and assessment of cardiovascular and offspring risk models for pregnant women with congenital heart disease. Heart. 2014;100(17):1373-81. 415. Thorne S, Nelson-Piercy C, MacGregor A, Gibbs S, Crowhurst J, Panay N, et al. Pregnancy and contraception in heart disease and pulmonary arterial hypertension. J Fam Plann Reprod Health Care. 2006;32(2):75-81. 416. Van Hagen IM, Boersma E, Johnson MR, Thorne SA, Parsonage WA, Escribano Subías P, et al. Global cardiac risk assessment in the registry of pregnancy and cardiac disease: results of a registry from the european society of cardiology. Eur J Heart Fail. 2016;18(5):523-33. 417. Curtis KM, Tepper NK, Jatlaoui TC, Berry-Bibee E, Horton LG, Zapata LB, et al. U.S. Medical Eligibility Criteria for ContraceptiveUse, 2016. MMWR Recomm Rep. 2016;65(3):1-103. 418. BonnemaRA,McNamaraMC,SpencerAL.Contraceptionchoicesinwomen with underlyingmedical conditions. AmFamPhysician. 2010;82(6):621-8. 419. Raccah-Tebeka B, Plu-Bureau G. Long-acting reversible contraception. Rev Prat. 2018;68(4):387-91. 420. Amies Oelschlager AM, Micks EA, Debiec KE, Nizamic T, Mantrala MD, Prager SW. Long acting reversible contraception in adolescents with cardiovascular conditions. J Pediatr Adolesc Gynecol. 2014;27(6):353-5. 421. World Health Organization (WHO). Medical eligibility criteria for contraceptive use. 5th ed. Geneva; 2015. 422. AvilaWS, GrinbergM, Melo NR, Pinotti JA, Pileggi F. Contraceptive use in women with heart disease. Arq Bras Cardiol. 1996;66(4):205-11. 423. Bonassi Machado R, Gandolpho AC, Santana N, Bocardo RC, Palandri N, Morassutti Machado R. Contraception for women with heart disease: an update. Minerva Ginecol. 2017;69(3):259-68. 941